P. Richardson

发表

Effi cacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission ( HPTN 046 ) : a randomised , double-blind , placebo-controlled trial

W. Fawzi, D. Moodley, L. Mofenson, 2011 .

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

K. Mayer, E. Fuchs, C. Hendrix, 2016, AIDS research and human retroviruses.

Depressive symptoms and use of HIV care and medication-assisted treatment among people living with HIV who inject drugs.

C. Latkin, W. Miller, D. Metzger, 2020, AIDS.

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

Myron S. Cohen, C. Hendrix, M. Marzinke, 2018, PLoS medicine.

Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.

K. Mayer, C. Hendrix, T. Wilkin, 2018, AIDS research and human retroviruses.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis

M. Hudgens, C. Latkin, W. Miller, 2018, Journal of the International AIDS Society.

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.

T. Holtz, C. del Rio, E. Daar, 2021, The New England journal of medicine.

The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women.

D. Moodley, H. McShane, H. Coovadia, 2014, Journal of acquired immune deficiency syndromes.

Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)

I. Frank, C. Hendrix, M. Marzinke, 2022, AIDS and Behavior.

Anaemia in Pregnancy Is Associated with Advanced HIV Disease

D. Moodley, A. Grobler, J. Bagratee, 2014, PloS one.

HIV Disease Progression in the First Year After Delivery Among African Women Followed in the HPTN 046 Clinical Trial

W. Fawzi, D. Moodley, H. Coovadia, 2013, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life

L. Mofenson, M. Fowler, T. Taha, 2014, Journal of acquired immune deficiency syndromes.

Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone: HIV Prevention Trials Network 058

D. Metzger, Y. Ruan, Y. Shao, 2015, Journal of acquired immune deficiency syndromes.

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

S. Delany-Moretlwe, J. Hughes, B. G. Mirembe, 2022, The Lancet.

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.

C. Hendrix, M. Marzinke, J. Eron, 2020, The lancet. HIV.

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.

S. Delany-Moretlwe, C. Petropoulos, J. Mellors, 2022, The Journal of infectious diseases.

Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women

I. Frank, K. Mayer, C. Hendrix, 2017, Annals of Internal Medicine.

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)

I. Frank, K. Mayer, C. Hendrix, 2016, The Journal of infectious diseases.

Impact of Maternal and Infant Antiretroviral Drug Regimens on Drug Resistance in HIV-infected Breastfeeding Infants

D. Moodley, L. Mofenson, H. Coovadia, 2013, The Pediatric infectious disease journal.

Association between drug use and ART use among people living with HIV who inject drugs in Vietnam, Ukraine and Indonesia: results from HPTN 074

W. Miller, I. Hoffman, K. Mollan, 2022, Journal of substance use.

A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study

M. Hudgens, C. Latkin, W. Miller, 2018, The Lancet.

HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074

W. Miller, I. Hoffman, W. Clarke, 2019, PloS one.

Use of Antiretroviral Drug Testing to Assess the Accuracy of Self-reported Data from HIV-Infected People Who Inject Drugs

W. Miller, I. Hoffman, W. Clarke, 2019, AIDS and Behavior.

Performance of the fourth-generation Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern Africa.

T. Coates, L. Richter, M. Marzinke, 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064

J. Justman, J. Hughes, M. Marzinke, 2015, PloS one.

Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1–Infected Women in Uganda (HPTN 027): The First Pediatric HIV Vaccine Trial in Africa

P. Kaleebu, N. Jones, M. Fowler, 2014, Journal of acquired immune deficiency syndromes.

The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.

Ross D. Cranston, K. Mayer, C. Hendrix, 2019, AIDS.

The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing PrEP Regimens in Men who have Sex with Men.

K. Mayer, C. Hendrix, M. Marzinke, 2018, AIDS.

EXTENDED PROPHYLAXIS WITH NEVIRAPINE DOES NOT AFFECT GROWTH IN HIV-EXPOSED INFANTS.

W. Fawzi, H. Coovadia, M. Fowler, 2019, Journal of acquired immune deficiency syndromes.

Cabotegravir for Prevention of HIV-1 in Women: Results From HPTN 084, a Phase III, Randomised Controlled Trial

S. Delany-Moretlwe, J. Hughes, M. Moorhouse, 2022, SSRN Electronic Journal.

Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial

W. Fawzi, D. Moodley, L. Mofenson, 2012, The Lancet.

Feasibility and Safety of ALVAC-HIV vCP1521 Vaccine in HIV-Exposed Infants in Uganda: Results From the First HIV Vaccine Trial in Infants in Africa

S. Gurunathan, M. Fowler, P. Musoke, 2013, Journal of acquired immune deficiency syndromes.

Causes and risk factors of death among people who inject drugs in Indonesia, Ukraine and Vietnam: findings from HPTN 074 randomized trial

C. Latkin, D. Metzger, I. Hoffman, 2023, BMC Infectious Diseases.

Efficacy and Safety of an Extended Nevirapine Regimen in Infants of Breastfeeding Mothers With HIV-1 Infection for Prevention of HIV-1 Transmission (HPTN 046): 18-Month Results of a Randomized, Double-Blind, Placebo-Controlled Trial

W. Fawzi, D. Moodley, L. Mofenson, 2014, Journal of acquired immune deficiency syndromes.

Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058.

D. Metzger, Y. Shao, D. Celentano, 2012, The International journal on drug policy.

Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women

J. Justman, L. Bekker, N. Mgodi, 2020, EClinicalMedicine.

Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.

D. Metzger, Y. Ruan, Y. Shao, 2014, Drug and alcohol dependence.

Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.

C. Hendrix, M. Marzinke, R. Landovitz, 2020, Journal of Acquired Immune Deficiency Syndromes.

Engaging People Who Inject Drugs Living With HIV in Antiretroviral Treatment and Medication for Opioid Use Disorder: Extended Follow-up of HIV Prevention Trials Network (HPTN) 074

M. Hudgens, C. Latkin, W. Miller, 2021, Open forum infectious diseases.

Metabolism of Long-Acting Rilpivirine Following Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076).

L. Bekker, N. Mgodi, C. Hendrix, 2020, AIDS research and human retroviruses.

The Pharmacokinetics, Pharmacodynamics, and Mucosal Responses to Maraviroc-Containing PrEP Regimens in Men who have Sex with Men

Ross D. Cranston, K. Mayer, C. Hendrix, 2019 .

Prevalence and Seroincidence of Hepatitis B and Hepatitis C Infection in High Risk People Who Inject Drugs in China and Thailand

D. Metzger, Y. Ruan, Y. Shao, 2014, Hepatitis research and treatment.

Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1–Infected Women in Uganda (HPTN 027): The First Pediatric HIV Vaccine Trial in Africa

P. Kaleebu, N. Jones, M. Fowler, 2014, Journal of acquired immune deficiency syndromes.